
    
      OUTLINE:

      Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive
      acalabrutinib orally (PO) every 12 hours. Treatment continues in the absence of disease
      progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel
      intravenously (IV) at 36-96 hours after completion of lymphodepleting chemotherapy.

      After completion of study treatment, patients are followed up every 3 months for up to 5
      years.
    
  